No overdose was reported.
Not available
Gastric- intestinal disorders :
Light gastrointestinal phenomena such as nausea, vomiting, diarrhea and abdominal pain were reported. Frequency unknown (cannot be estimated according to data).
Violations of the immune system :
Hypersensitivity reactions were reported (mainly after parenteral administration). In isolated cases, allergic and anaphylactic reactions with symptoms of itching, urticaria, itching, urticaria, angioneurotic edema, abdominal pain, respiratory disorders, tachycardia, heartbeat and shock were reported. Frequency unknown (cannot be estimated according to data).
Report alleged adverse reactions
It is important to report suspicious adverse reactions after obtaining permission to use the drug. This allows you to continue monitoring the balance of use / risk of the drug. Health workers are requested to report any suspicious side reactions through the Yellow Card System, website: www.mhra.gov.uk/yellowcard.
No data
Beneerva deficiency treatment
ATH code: A11DA01
Pharmacotherapeutic group: Vitamin B1, Normal
Benerva is an important investment of carbohydrate metabolism.
The boost is well absorbed from the gastrointestinal tract after being taken inward, although suction of large doses is limited. It is widespread in most tissues of the body and appears in breast milk. Inside the cell, Benerva is mainly present in the form of diphosphate. Beneurva does not accumulate in the body to any noticeable degree, quantities exceeding the needs of the body are excreted with urine in the form of a constant Beneurve or metabolites.
Beneerva
Thiamina hydrochloride
This medicine contains lactose monohydrate. Patients with rare hereditary problems of the intolerance of galactose, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicine also contains sucrose. Patients with rare hereditary problems of fructose intolerance, malabsorption or deficiency of isomalous sucrose should not take this medicine
No studies have been conducted on the ability to drive and use cars. However, patients must be warned to see how they react before driving or working with mechanisms.
Adults, Elderly and Children over three years old :
Light chronic deficiency: 50 mg per day
Severe deficit: 100 mg three times a day.
Not recommended for children under three years old.
Method of introduction : oral
None
